Docosahexaenoic acid withstands the Aβ25-35-induced neurotoxicity in SH-SY5Y cells

Journal of Nutritional Biochemistry

Volumn 22, Issue 1, 2011, Pages 22-29

  Hashimoto, Michio ^a   Katakura, Masanori ^b   Hossain, Shahdat ^a,b   Rahman, Azizur ^a,b   Shimada, Toshio ^a   Shido, Osamu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

Author keywords

A 25 35 fibrillation; Docosahexaenoic acid; Neurotoxicity; SH SY5Y cells

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; DOCOSAHEXAENOIC ACID; FATTY ACID; LIPID PEROXIDE;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; FATTY ACID ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NEUROTOXICITY; NICK END LABELING; OXIDATION REDUCTION STATE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; APOPTOSIS; AXONS; CELL LINE; CELL SURVIVAL; DENDRITES; DNA DAMAGE; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; HUMANS; IN SITU NICK-END LABELING; LIPID PEROXIDES; NEURONS; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS;

EID: 78649922280     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.11.005     Document Type: Article

References (48)

1. Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002, 81:1084-1091.
2. Hashimoto M., Tanabe Y., Fujii Y., Kikuta T., Shibata H., Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid β-infused rats. J Nutr 2005, 135:549-555.
3. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005, 25:3032-3040.
4. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., et al. Plasma Phosphatidylcholine Docosahexaenoic acid content and risk of dementia and Alzheimer disease The Framingham Heart Study. Arch Neurol 2006, 63:1545-1550.
5. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
6. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 1994, 13:45-53.
7. Kubo T., Nishimura S., Kumagae Y., Kaneko I. In vivo conversion of racemized β-amyloid ([D-Ser 26]Aβ 1-40) to truncated and toxic fragments ([D-Ser 26]A 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 2002, 70:474-483.
8. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990, 250(4978):279-282.
9. Xu J., Chen S., Ahmed S.H., Chen H., Ku G., Golberg M.P., et al. Amyloid-β peptides are cytotoxic to oligodendrocytes. J Neurosci 2001, 21:RC118:1-5.
10. Hashimoto M., Shahdat H.M., Katakura M., Tanabe Y., Gamoh S., Miwa K., et al. Effects of docosahexaenoic acid on in vitro amyloid β25-35 fibrillation. Biochimca Biophysca Acta 2009, 1791:289-296.
11. Hashimoto M., Shahdat H.M., Yamashita S., Katakura M., Tanabe Y., Fujiwara H., et al. Docosahexaenoic acid disrupts in vitro amyloid β fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. J Neurochem 2008, 107:1634-1646.
12. Yamada M., Chiba T., Sasabe J., Nawa M., Tajima H., Niikura T., et al. Implanted cannula-mediated repetitive administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res 2005, 164:139-146.
13. Crawford M. The role of essential fatty acids in neural development: implications for perinatal nutrition. Am J Clin Nutr 1993, 57:703S-710S.
14. Lauritzen L., Hansen H.S., Jorgensen M.H., Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 2001, 40:1-94.
15. Innis S.M. Dietary (n-3) fatty acids and brain development. J Nutr 2007, 137:855-859.
16. Söderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
17. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998, 23:81-88.
18. Moore S.A. Polyunsaturated fatty acid synthesis and release by brain-derived cells in vitro. J Mol Neurosci 2003, 16:195-200.
19. Lukiw W.L., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005, 115:2774-2783.
20. Lepage G., Roy C.C. Direct transesterification of all classes of lipids in a one- step reaction. J Lipid Res 1986, 27:114-120.
21. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95:351-358.
22. Hossain M.S., Hashimoto M., Gamoh S., Masumura S. Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 1999, 72:1133-1138.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin reagent. J Biol Chem 1951, 193:265-275.
24. Haass C., Selkoe D. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 1993, 75:1039-1042.
25. Cai X.D., Golde T.E., Younkin S.G. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 1993, 259:514-516.
26. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:3270-3274.
27. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease?. Neurobiol Aging 1995, 16:661-674.
28. Cotman C., Anderson A. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995, 10:19-45.
29. Behl C., Davis J., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid b protein toxicity. Cell 1994, 77:817-827.
30. Shearman M.S., Hawtin S.R., Tailor V.J. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides. J Neurochem 1995, 65:218-227.
31. Reynolds L.M., Dalton C.F., Reynolds G.P. Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Letts 2001, 309:193-196.
32. Pilitsis J.G., Diaz F.G., Wellwood J.M., O'Regan M.H., Fairfax M.R., Phillis J.W., et al. Quantification of free fatty acids in human cerebrospinal fluid. Neurochem Res 2001, 26:1265-1270.
33. Halliwell B., Chirico S. Lipid peroxidation: its mechanisms, measurement, and significance. Am J Clin Nutr 1993, 57(Suppl):715S-725S.
34. Song J.H., Fujimoto K., Miyazawa T. Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils. J Nutr 2000, 130:3028-3033.
35. Bechoua S., Dubois M., Dominguez Z., Goncalves A., Némoz G., Lagarde M., et al. Protective effect of docosahexaenoic acid against hydrogen peroxide-induced oxidative stress in human lymphocytes. Biochem Pharmacol 1999, 57:1021-1030.
36. Lindskog M., Gleissman H., Ponthan F., Castro J., Kogner P., Johnsen J.I. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 2006, 118:2584-2593.
37. Kim H.Y., Akbar M., Kim K.Y. Inhibition of neuronal apoptosis by polyunsaturated fatty acids. J Mol Neurosci 2001, 16:223-227.
38. Yavin E., Brand A., Green P. Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr Neurosci 2002, 5:149-157.
39. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139:991-997.
40. Katakura M., Hashimoto M., Shahdat H.M., Gamoh S., et al. Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop-helix transcription factors and cell cycle in neural stem cells. Neuroscience 2009, 160:651-660.
41. Kim H.-Y., Akbar M., Lau A., Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). J Biol Chem 2000, 275:35215-35223.
42. Alexander-North L.S., North J.A., Kiminyo K.P., Buettner G.R., Spector A.A. Polyunsaturated fatty acids increase lipid radical formation induced by oxidant stress in endothelial cells. J Lipid Res 1994, 35:1773-1785.
43. Arita K., Kobuchi H., Utsumi T., Takehara Y., Akiyama J., Horton A.A., et al. Mechanism of apoptosis in HL-60 cells induced by n-3 and n-6 polyunsaturated fatty acids. Biochem Pharmacol 2001, 62:821-828.
44. Rotstein N.P., Politi L.F., German O.L., Girotti R. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Invest Ophthalmol Vis Sci 2003, 44:2252-2259.
45. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002, 36:1307-1313.
46. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 1999, 20:325-330. [discussion 339-342].
47. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanye M.C., et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid- b oligomers. J Neurochem 2006, 96:385-395.
48. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 2004, 18:1427-1429.